Skye Bioscience Stock
Skye Bioscience, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Punit Dhillon
- Employees
- 2
- Market cap
- $7 M
- IPO
- 06/01/2015
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting…
Skye Bioscience stock: price history
1D
-2.5%
1W
-8.3%
1M
-8.8%
6M
-75.4%
YTD
-74.2%
1Y
-86.6%
2Y
-95.5%
5Y
-98.9%
10Y
-99.8%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~19% weaker price swings than usual
Ask the agents about Skye Bioscience
Analyst assessment of Skye Bioscience
PRICE TARGET LOW
US$2.00
CONSENSUS
US$12.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$21.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 24/06/2025
Skye Bioscience stock metrics
P/E
-0.15
P/B
-15.46
EV/EBITDA
0.02
RETURN ON EQUITY
2,169.0%
NET MARGIN
0.0%
DEBT/EQUITY
-0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
67.2%
FLOAT SHARES
2,977,154
AVG. DAILY VOLUME (30D)
65,272
Insider transactions (SEC)
Schwab Andrew J.
5AM Partners VII, LLC
Schwab Andrew J.
Schwab Andrew J.
Schwab Andrew J.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Skye Bioscience stock
What does Skye Bioscience do?
Skye Bioscience, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Punit Dhillon, the company employs around 2 people.
The IPO was on 06/01/2015; the stock trades on NASDAQ under the ticker SKYE.
What do analysts say about Skye Bioscience stock?
5 analysts rate the stock, the consensus is Buy (as of 24/06/2025).
The average price target is US$12.00, ranging from US$2.00 to US$21.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Skye Bioscience report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -19% stronger than usual.
Does Skye Bioscience pay a dividend?
No, Skye Bioscience currently does not pay a dividend.
Which stocks are comparable to Skye Bioscience?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Skye Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Skye Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.